One-third of the world’s population will face a cancer diagnosis in their lifetime.
Did you know that there is a target behind over half of all cancers—from children to adults—yet considered “untouchable” in the world of medicine? MYC is a protein which controls critical functions and when deregulated leads to tumors, causing uncontrolled growth, aggressive spread and resistance to existing treatments. Patients with MYC-driven tumors often face particularly aggressive, high-risk cancers, resulting in poor prognosis and limited or no effective treatment options. Tragically, this means many patients don’t even receive adequate treatment due to the absence of viable therapies.
MyCural Therapeutics – Developing a next-generation cancer therapy
Empowered by a world-class team of scientists with innovative drug development strategies, MyCural is transforming MYC from an untouchable target into a therapeutic breakthrough, paving the way for next-generation cancer treatments.
Founded by experienced scientists and backed by over 20 years of dedicated research from three leading Swedish universities—Karolinska Institutet, Uppsala University, and Linköping University—MyCural is uniquely positioned to transform cancer care and deliver life-changing therapies.
